Wave Neuroscience has secured Food and Drug Administration clearance for a personalized magnetic brain stimulation system for post-traumatic stress disorder, achieving a 52 percent reduction in symptoms and a 68 percent remission rate in clinical trials, according to sciencedaily.com.
How Magnetic e-Resonance Therapy Targets Brain Activity
The newly cleared system uses Magnetic e-Resonance Therapy, or MeRT, which combines electroencephalogram brain activity measurements with transcranial magnetic stimulation. During standard transcranial magnetic stimulation, a coil positioned against the scalp delivers magnetic pulses to stimulate brain activity, a technique previously cleared by the FDA for treatment-resistant depression. What distinguishes MeRT is its use of an artificial intelligence-assisted algorithm to customize stimulation protocols based on each patient’s individual brain activity rather than relying on a standardized approach.
Erik Won, chief medical officer at Wave Neuroscience, noted that the clinical trial results mark a major advance over traditional medication outcomes. In comparison to a 2020 review of post-traumatic stress disorder medications where remission rates reached only 10.9 percent at most, the MeRT clinical trial reported a 68 percent remission rate. Kenneth S. Ramos of Texas A&M Health, who guided the research alongside executive director of clinical trials Rick Silva, emphasized that tailoring stimulation to biological differences helps address conditions where conventional interventions fall short.
In Plain English: The Clinical Takeaway
- Targeted Stimulation: The MeRT system reads individual brain electrical signals via electroencephalogram to customize magnetic pulse therapy, differing from one-size-fits-all transcranial magnetic stimulation.
- Clinical Efficacy: Clinical trials showed a 52 percent symptom reduction and a 68 percent remission rate among participants undergoing five weekly sessions for five to six weeks.
- Drug-Free Alternative: The system provides a non-medication option for patients who experience limited relief or severe side effects from selective serotonin reuptake inhibitors like sertraline and fluoxetine.
Expanding Options Beyond Medications and Psychotherapy
Since post-traumatic stress disorder was formally recognized as a diagnosis in 1980, treatment has largely centered on psychotherapy and selective serotonin reuptake inhibitors such as sertraline and fluoxetine. However, many patients continue to experience symptoms despite receiving treatment.
The MeRT system provides an FDA-cleared non-medication alternative that does not carry the chemical side effects associated with traditional psychiatric drugs. The regulatory process for the device advanced rapidly following an FDA Breakthrough Device designation in 2024, moving from development to clearance in just over two years.
| Treatment Category | Primary Intervention | Reported Efficacy / Remission |
|---|---|---|
| Standard Pharmacotherapy | SSRIs (e.g., sertraline, fluoxetine) | Remission rates up to 10.9% (2020 review) |
| Standard Psychotherapy | Trauma-focused talk therapy | Variable; high attrition due to anxiety |
| Personalized Brain Stimulation | MeRT (AI-guided TMS) | 68% remission rate in clinical trial |
Contraindications & When to Consult a Doctor
Patients with metallic implants in the head, implanted electrical devices such as pacemakers, or a history of seizure disorders should exercise caution, as transcranial magnetic stimulation involves strong magnetic fields. Individuals experiencing severe psychiatric distress, suicidal ideation, or worsening post-traumatic stress symptoms should immediately consult a licensed psychiatrist, physician, or emergency mental health services for comprehensive evaluation and triage.
Pathways to Patient Access and Insurance Coverage
Following the regulatory clearance, Wave Neuroscience and Texas A&M Health are collaborating with stakeholders to expand availability and work toward insurance coverage that makes the therapy more affordable. Leslie S. Prichep, chief scientific officer at Wave Neuroscience, noted that the clearance reflects decades of research utilizing electrophysiological biomarkers to guide personalized interventions. Company executives intend for the technology to establish a more objective, data-informed model of mental healthcare that reduces public stigma surrounding psychiatric conditions by grounding diagnoses in measurable physiological data.
References
- Annual Report Part 2.
